Actos

Negara: Uni Eropa

Bahasa: Inggris

Sumber: EMA (European Medicines Agency)

Beli Sekarang

Selebaran informasi Selebaran informasi (PIL)
28-08-2023
Karakteristik produk Karakteristik produk (SPC)
28-08-2023

Bahan aktif:

pioglitazone hydrochloride

Tersedia dari:

CHEPLAPHARM Arzneimittel GmbH

Kode ATC:

A10BG03

INN (Nama Internasional):

pioglitazone

Kelompok Terapi:

Drugs used in diabetes

Area terapi:

Diabetes Mellitus, Type 2

Indikasi Terapi:

Pioglitazone is indicated in the treatment of type-2 diabetes mellitus:as monotherapy:in patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance;as dual oral therapy in combination with:metformin, in patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin;a sulphonylurea, only in patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea;as triple oral therapy in combination with:metformin and a sulphonylurea, in patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy.Pioglitazone is also indicated for combination with insulin in type-2 diabetes mellitus patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance.

Ringkasan produk:

Revision: 30

Status otorisasi:

Authorised

Tanggal Otorisasi:

2000-10-13

Selebaran informasi

                                28
B. PACKAGE LEAFLET
29
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
ACTOS 15 MG TABLETS
ACTOS 30 MG TABLETS
ACTOS 45 MG TABLETS
pioglitazone
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Actos is and what it is used for
2.
What you need to know before you take Actos
3.
How to take Actos
4.
Possible side effects
5.
How to store Actos
6.
Contents of the pack and other information
1.
WHAT ACTOS IS AND WHAT IT IS USED FOR
Actos contains pioglitazone. It is an anti-diabetic medicine used to
treat type 2 (non-insulin dependent)
diabetes mellitus in adults, when metformin is not suitable or has
failed to work adequately. This is the
diabetes that usually develops in adulthood.
Actos helps control the level of sugar in your blood when you have
type 2 diabetes by helping your
body make better use of the insulin it produces. Your doctor will
check whether Actos is working 3 to
6 months after you start taking it.
Actos may be used on its own in patients who are unable to take
metformin, and where treatment with
diet and exercise has failed to control blood sugar or may be added to
other therapies (such as
metformin, sulphonylurea or insulin) which have failed to provide
sufficient control of blood sugar.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE ACTOS
DO NOT TAKE ACTOS
-
if you are allergic to pioglitazone or any of the other ingredients of
this medicine (listed in
section 6).
-
if you have heart failure or have had heart failure in the past.
-
if you have liver disease.
-
if you have had diabetic ketoa
                                
                                Baca dokumen lengkapnya
                                
                            

Karakteristik produk

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Actos 15 mg tablets
Actos 30 mg tablets
Actos 45 mg tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Actos 15 mg tablets
Each tablet contains 15 mg of pioglitazone (as hydrochloride).
_Excipient with known effect_
Each tablet contains 92.87 mg of lactose monohydrate (see section
4.4).
Actos 30 mg tablets
Each tablet contains 30 mg of pioglitazone (as hydrochloride).
_Excipient with known effect_
Each tablet contains 76.34 mg of lactose monohydrate (see section
4.4).
Actos 45 mg tablets
Each tablet contains 45 mg of pioglitazone (as hydrochloride).
_Excipient with known effect_
Each tablet contains 114.51 mg of lactose monohydrate (see section
4.4).
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Tablet
Actos 15 mg tablets
The tablets are white to off-white, round, convex and marked ‘15’
on one face and ‘ACTOS’ on the
other face.
Actos 30 mg tablets
The tablets are white to off-white, round, flat and marked ‘30’ on
one face and ‘ACTOS’ on the other
face.
Actos 45 mg tablets
The tablets are white to off-white, round, flat and marked ‘45’ on
one face and ‘ACTOS’ on the other
face.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Pioglitazone is indicated as second or third line treatment of type 2
diabetes mellitus as described
below:
3
as
MONOTHERAPY
-
in adult patients (particularly overweight patients) inadequately
controlled by diet and
exercise for whom metformin is inappropriate because of
contraindications or
intolerance
as
DUAL ORAL THERAPY
in combination with
-
metformin, in adult patients (particularly overweight patients) with
insufficient
glycaemic control despite maximal tolerated dose of monotherapy with
metformin
-
a sulphonylurea, only in adult patients who show intolerance to
metformin or for
whom metformin is contraindicated, with insufficient glycaemic control
despite
maximal tolerated dose of monotherapy with a sulphonylurea.
as
TRIPLE ORAL THERAPY
in combination 
                                
                                Baca dokumen lengkapnya
                                
                            

Dokumen dalam bahasa lain

Selebaran informasi Selebaran informasi Bulgar 28-08-2023
Karakteristik produk Karakteristik produk Bulgar 28-08-2023
Laporan Penilaian publik Laporan Penilaian publik Bulgar 29-09-2016
Selebaran informasi Selebaran informasi Spanyol 28-08-2023
Karakteristik produk Karakteristik produk Spanyol 28-08-2023
Laporan Penilaian publik Laporan Penilaian publik Spanyol 29-09-2016
Selebaran informasi Selebaran informasi Cheska 28-08-2023
Karakteristik produk Karakteristik produk Cheska 28-08-2023
Laporan Penilaian publik Laporan Penilaian publik Cheska 29-09-2016
Selebaran informasi Selebaran informasi Dansk 28-08-2023
Karakteristik produk Karakteristik produk Dansk 28-08-2023
Laporan Penilaian publik Laporan Penilaian publik Dansk 29-09-2016
Selebaran informasi Selebaran informasi Jerman 28-08-2023
Karakteristik produk Karakteristik produk Jerman 28-08-2023
Laporan Penilaian publik Laporan Penilaian publik Jerman 29-09-2016
Selebaran informasi Selebaran informasi Esti 28-08-2023
Karakteristik produk Karakteristik produk Esti 28-08-2023
Laporan Penilaian publik Laporan Penilaian publik Esti 29-09-2016
Selebaran informasi Selebaran informasi Yunani 28-08-2023
Karakteristik produk Karakteristik produk Yunani 28-08-2023
Laporan Penilaian publik Laporan Penilaian publik Yunani 29-09-2016
Selebaran informasi Selebaran informasi Prancis 28-08-2023
Karakteristik produk Karakteristik produk Prancis 28-08-2023
Laporan Penilaian publik Laporan Penilaian publik Prancis 29-09-2016
Selebaran informasi Selebaran informasi Italia 28-08-2023
Karakteristik produk Karakteristik produk Italia 28-08-2023
Laporan Penilaian publik Laporan Penilaian publik Italia 29-09-2016
Selebaran informasi Selebaran informasi Latvi 28-08-2023
Karakteristik produk Karakteristik produk Latvi 28-08-2023
Laporan Penilaian publik Laporan Penilaian publik Latvi 29-09-2016
Selebaran informasi Selebaran informasi Lituavi 28-08-2023
Karakteristik produk Karakteristik produk Lituavi 28-08-2023
Laporan Penilaian publik Laporan Penilaian publik Lituavi 29-09-2016
Selebaran informasi Selebaran informasi Hungaria 28-08-2023
Karakteristik produk Karakteristik produk Hungaria 28-08-2023
Laporan Penilaian publik Laporan Penilaian publik Hungaria 29-09-2016
Selebaran informasi Selebaran informasi Malta 28-08-2023
Karakteristik produk Karakteristik produk Malta 28-08-2023
Laporan Penilaian publik Laporan Penilaian publik Malta 29-09-2016
Selebaran informasi Selebaran informasi Belanda 28-08-2023
Karakteristik produk Karakteristik produk Belanda 28-08-2023
Laporan Penilaian publik Laporan Penilaian publik Belanda 29-09-2016
Selebaran informasi Selebaran informasi Polski 28-08-2023
Karakteristik produk Karakteristik produk Polski 28-08-2023
Laporan Penilaian publik Laporan Penilaian publik Polski 29-09-2016
Selebaran informasi Selebaran informasi Portugis 28-08-2023
Karakteristik produk Karakteristik produk Portugis 28-08-2023
Laporan Penilaian publik Laporan Penilaian publik Portugis 29-09-2016
Selebaran informasi Selebaran informasi Rumania 28-08-2023
Karakteristik produk Karakteristik produk Rumania 28-08-2023
Laporan Penilaian publik Laporan Penilaian publik Rumania 29-09-2016
Selebaran informasi Selebaran informasi Slovak 28-08-2023
Karakteristik produk Karakteristik produk Slovak 28-08-2023
Laporan Penilaian publik Laporan Penilaian publik Slovak 29-09-2016
Selebaran informasi Selebaran informasi Sloven 28-08-2023
Karakteristik produk Karakteristik produk Sloven 28-08-2023
Laporan Penilaian publik Laporan Penilaian publik Sloven 29-09-2016
Selebaran informasi Selebaran informasi Suomi 28-08-2023
Karakteristik produk Karakteristik produk Suomi 28-08-2023
Laporan Penilaian publik Laporan Penilaian publik Suomi 29-09-2016
Selebaran informasi Selebaran informasi Swedia 28-08-2023
Karakteristik produk Karakteristik produk Swedia 28-08-2023
Laporan Penilaian publik Laporan Penilaian publik Swedia 29-09-2016
Selebaran informasi Selebaran informasi Norwegia 28-08-2023
Karakteristik produk Karakteristik produk Norwegia 28-08-2023
Selebaran informasi Selebaran informasi Islandia 28-08-2023
Karakteristik produk Karakteristik produk Islandia 28-08-2023
Selebaran informasi Selebaran informasi Kroasia 28-08-2023
Karakteristik produk Karakteristik produk Kroasia 28-08-2023
Laporan Penilaian publik Laporan Penilaian publik Kroasia 29-09-2016

Peringatan pencarian terkait dengan produk ini

Lihat riwayat dokumen